Back to top

gene-editing: Archive

Ekta Bagri

Intellia Crashes 60% in a Year: How Should You Play the Stock?

NTLA stock is down significantly in 2024 as investors are not pleased with the recent data from its in vivo CRISPR-based therapies. We advise prospective investors to stay on the sidelines for now.

REGNPositive Net Change IONSPositive Net Change NTLANegative Net Change CRSPNegative Net Change

Zacks Equity Research

RARE Submits BLA to the FDA for Sanfilippo Syndrome Gene Therapy

Ultragenyx submits a BLA to the FDA seeking the accelerated approval of UX111 for patients with Sanfilippo syndrome type A in the United States.

RARENegative Net Change CTMXPositive Net Change SPROPositive Net Change CSTLNegative Net Change

Zacks Equity Research

EDIT Stock Falls on Decision to End Reni-Cel Studies, Cut Workforce

Editas stock falls as it ends development of reni-cel for SCD and TDT following failed attempts to find a commercial partner. It plans to cut workforce by 65%.

EDITNegative Net Change CTMXPositive Net Change SPROPositive Net Change CSTLNegative Net Change

Zacks Equity Research

QURE Soars on FDA Alignment for Speedy Approval of Huntington's Drug

uniQure stock rallies 110% on reaching alignment with the FDA on key elements of an accelerated approval pathway for AMT-130 to treat Huntington's disease.

ALNYPositive Net Change PFEPositive Net Change GILDPositive Net Change QURENegative Net Change